Peringatan Keamanan

Overdosage is characterised by nausea, agitation and restlessness, dryness of the mouth, dizziness and tremor. In gross overdosage the above symptoms may also be associated with dyspnoea, tachycardia, disorientation and convulsions.

Fencamfamin

DB01463

small molecule experimental illicit withdrawn

Deskripsi

Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. Fencamfamin is used for treating depressive day-time fatigue, lack of concentration and lethargy. It is especially useful in patients with chronic conditions due to its favourable safety profile.

Struktur Molekul 2D

Berat 215.3339
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

663 Data
Buprenorphine Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamin.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Fencamfamin.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Fencamfamin.
Hydrocodone Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamin.
Magnesium sulfate The therapeutic efficacy of Fencamfamin can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Fencamfamin may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fencamfamin.
Mirtazapine Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Fencamfamin.
Orphenadrine Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Fencamfamin.
Pramipexole Fencamfamin may increase the sedative activities of Pramipexole.
Ropinirole Fencamfamin may increase the sedative activities of Ropinirole.
Rotigotine Fencamfamin may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Fencamfamin.
Sodium oxybate Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fencamfamin.
Thalidomide Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Fencamfamin.
Ethanol Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamin.
Zimelidine The risk or severity of adverse effects can be increased when Fencamfamin is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Fencamfamin is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Fencamfamin is combined with Seproxetine.
Fluvoxamine The risk or severity of adverse effects can be increased when Fencamfamin is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Fencamfamin is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Fencamfamin is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Fencamfamin is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Fencamfamin is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Fencamfamin is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Fencamfamin is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Fencamfamin is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Fencamfamin is combined with Escitalopram.
Milnacipran The risk or severity of adverse effects can be increased when Fencamfamin is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Fencamfamin is combined with Desvenlafaxine.
Levomilnacipran The risk or severity of adverse effects can be increased when Fencamfamin is combined with Levomilnacipran.
Indalpine The risk or severity of adverse effects can be increased when Fencamfamin is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Fencamfamin is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Fencamfamin is combined with Alaproclate.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Fencamfamin.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Fencamfamin.
Zopiclone The risk or severity of adverse effects can be increased when Fencamfamin is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Fencamfamin.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Fencamfamin.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Fencamfamin.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Fencamfamin.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Fencamfamin.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Fencamfamin.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Fencamfamin.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Fencamfamin.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Fencamfamin.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Fencamfamin.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Fencamfamin.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Fencamfamin.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Fencamfamin.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Fencamfamin.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Fencamfamin.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Fencamfamin.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Fencamfamin.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Fencamfamin.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Fencamfamin.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Fencamfamin.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Fencamfamin.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Fencamfamin.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Fencamfamin.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Fencamfamin.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Fencamfamin.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Fencamfamin.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Fencamfamin.
Palonosetron The risk or severity of CNS depression can be increased when Palonosetron is combined with Fencamfamin.
Dexbrompheniramine The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Fencamfamin.
Metocurine iodide The risk or severity of CNS depression can be increased when Metocurine iodide is combined with Fencamfamin.
Secobarbital The risk or severity of CNS depression can be increased when Secobarbital is combined with Fencamfamin.
Methocarbamol The risk or severity of CNS depression can be increased when Methocarbamol is combined with Fencamfamin.
Triprolidine The risk or severity of CNS depression can be increased when Triprolidine is combined with Fencamfamin.
Meperidine The risk or severity of CNS depression can be increased when Meperidine is combined with Fencamfamin.
Metharbital The risk or severity of CNS depression can be increased when Metharbital is combined with Fencamfamin.
Quinine The risk or severity of CNS depression can be increased when Quinine is combined with Fencamfamin.
Methohexital The risk or severity of CNS depression can be increased when Methohexital is combined with Fencamfamin.
Gallamine triethiodide The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Fencamfamin.
Entacapone The risk or severity of CNS depression can be increased when Entacapone is combined with Fencamfamin.
Oxycodone The risk or severity of CNS depression can be increased when Oxycodone is combined with Fencamfamin.
Dextromethorphan The risk or severity of CNS depression can be increased when Dextromethorphan is combined with Fencamfamin.
Mephenytoin The risk or severity of CNS depression can be increased when Mephenytoin is combined with Fencamfamin.
Cisatracurium The risk or severity of CNS depression can be increased when Cisatracurium is combined with Fencamfamin.
Fenfluramine The risk or severity of CNS depression can be increased when Fenfluramine is combined with Fencamfamin.
Mazindol The risk or severity of CNS depression can be increased when Mazindol is combined with Fencamfamin.
Fluticasone propionate The risk or severity of CNS depression can be increased when Fluticasone propionate is combined with Fencamfamin.
Lisuride The risk or severity of CNS depression can be increased when Lisuride is combined with Fencamfamin.
Ethosuximide The risk or severity of CNS depression can be increased when Ethosuximide is combined with Fencamfamin.
Thiopental The risk or severity of CNS depression can be increased when Thiopental is combined with Fencamfamin.
Cisapride The risk or severity of CNS depression can be increased when Cisapride is combined with Fencamfamin.
Butorphanol The risk or severity of CNS depression can be increased when Butorphanol is combined with Fencamfamin.

Target Protein

Sodium-dependent dopamine transporter SLC6A3
D(2) dopamine receptor DRD2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 1970543
    DeLucia R, Planeta CS: Fencamfamine. Gen Pharmacol. 1990;21(2):161-3.
Link

Contoh Produk & Brand

Produk: 0 • International brands: 2
International Brands
  • Glucoenergan
  • Reactivan

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul